The purpose of this study is to determine the safety and effect of CAL-263 in subjects with allergic rhinitis.
A Phase I, randomized, double-blind crossover study of CAL-263, an oral inhibitor of PI3K delta, in patients with allergic rhinitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
48
Vienna Challenge Chamber
Vienna, Austria
Evaluate the safety of CAL-263 in allergic rhinitis subjects
Time frame: 46 days
Determine the efficacy of CAL-263 on total nasal symptom scores following an allergen challenge in allergic rhinitis subjects
Time frame: 7 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.